Back to Journals » Drug Design, Development and Therapy » Volume 7

Drug Design, Development and Therapy


Archive: Volume 7, 2013

Disease-modifying drugs in Alzheimer's disease

Ghezzi L, Scarpini E, Galimberti D

Drug Design, Development and Therapy 2013, 7:1471-1479

Published Date: 6 December 2013

Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain – an in vivo study

Udvardi PT, Föhr KJ, Henes C, Liebau S, Dreyhaupt J, Boeckers TM, Ludolph AG

Drug Design, Development and Therapy 2013, 7:1433-1446

Published Date: 4 December 2013

Combined letrozole and clomiphene versus letrozole and clomiphene alone in infertile patients with polycystic ovary syndrome

Hajishafiha M, Dehghan M, Kiarang N, Sadegh-Asadi N, Shayegh SN, Ghasemi-Rad M

Drug Design, Development and Therapy 2013, 7:1427-1431

Published Date: 3 December 2013

Conversion to generic cyclosporine A in stable chronic patients after heart transplantation

Kraeuter M, Helmschrott M, Erbel C, Gleissner CA, Frankenstein L, Schmack B, Ruhparwar A, Ehlermann P, Katus HA, Doesch AO

Drug Design, Development and Therapy 2013, 7:1421-1426

Published Date: 28 November 2013

Estrogen receptor modulatory effects of germinated brown rice bioactives in the uterus of rats through the regulation of estrogen-induced genes

Muhammad SI, Maznah I, Mahmud RB, Saeed MI, Imam MU, Ishaka A

Drug Design, Development and Therapy 2013, 7:1409-1420

Published Date: 2 December 2013

Canagliflozin: a novel treatment option for type 2 diabetes

Dietrich E, Powell J, Taylor JR

Drug Design, Development and Therapy 2013, 7:1399-1408

Published Date: 22 November 2013

Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?

Theron AJ, Steel HC, Tintinger GR, Feldman C, Anderson R

Drug Design, Development and Therapy 2013, 7:1387-1398

Published Date: 22 November 2013

In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models

Schleiferböck S, Scheurer C, Ihara M, Itoh I, Bathurst I, Burrows JN, Fantauzzi P, Lotharius J, Charman SA, Morizzi J, Shackleford DM, White KL, Brun R, Wittlin S

Drug Design, Development and Therapy 2013, 7:1377-1384

Published Date: 15 November 2013

Antituberculosis nanodelivery system with controlled-release properties based on para-amino salicylate–zinc aluminum-layered double-hydroxide nanocomposites

Saifullah B, Hussein MZ, Hussein-Al-Ali SH, Arulselvan P, Fakurazi S

Drug Design, Development and Therapy 2013, 7:1365-1375

Published Date: 13 November 2013

Profile of gantenerumab and its potential in the treatment of Alzheimer's disease

Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi C, Errico F, Mercuri NB, Nicoletti F, Nisticò R

Drug Design, Development and Therapy 2013, 7:1359-1364

Published Date: 13 November 2013

Animal models of ulcerative colitis and their application in drug research

Low D, Nguyen DD, Mizoguchi E

Drug Design, Development and Therapy 2013, 7:1341-1357

Published Date: 12 November 2013

New and emerging treatments for symptomatic tardive dyskinesia

Rana AQ, Chaudry ZM, Blanchet PJ

Drug Design, Development and Therapy 2013, 7:1329-1340

Published Date: 6 November 2013

Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study

Doesch AO, Mueller S, Erbel C, Gleissner CA, Frankenstein L, Hardt S, Ruhparwar A, Ehlermann P, Dengler T, Katus HA

Drug Design, Development and Therapy 2013, 7:1323-1328

Published Date: 5 November 2013

Molecularly targeted drugs for metastatic colorectal cancer

Cheng YD, Yang H, Chen GQ, Zhang ZC

Drug Design, Development and Therapy 2013, 7:1315-1322

Published Date: 1 November 2013

Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFNα triggering apoptosis, autophagy and senescence

Marchal JA, Carrasco E, Ramírez A, Jiménez G, Olmedo C, Peran M, Agil A, Conejo-García A, Cruz-López O, Campos JM, García MA

Drug Design, Development and Therapy 2013, 7:1301-1313

Published Date: 29 October 2013

Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells

Cheng M, Xu H, Wang Y, Chen H, He B, Gao X, Li Y, Han J, Zhang Z

Drug Design, Development and Therapy 2013, 7:1287-1299

Published Date: 25 October 2013

Advances in the proteomic discovery of novel therapeutic targets in cancer

Guo S, Zou J, Wang G

Drug Design, Development and Therapy 2013, 7:1259-1271

Published Date: 24 October 2013

Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation

Doesch AO, Mueller S, Akyol C, Erbel C, Frankenstein L, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA

Drug Design, Development and Therapy 2013, 7:1253-1258

Published Date: 21 October 2013

Antioxidant effect of Arabic gum against mercuric chloride-induced nephrotoxicity

Gado AM, Aldahmash BA

Drug Design, Development and Therapy 2013, 7:1245-1252

Published Date: 21 October 2013

Intestinal absorption and biliary elimination of glycyrrhizic acid diethyl ester in rats

Koga K, Kawamura M, Iwase H, Yoshikawa N

Drug Design, Development and Therapy 2013, 7:1235-1243

Published Date: 21 October 2013

Daclatasvir: potential role in hepatitis C

Lee C

Drug Design, Development and Therapy 2013, 7:1223-1233

Published Date: 16 October 2013

Current and future G protein-coupled receptor signaling targets for heart failure therapy

Siryk-Bathgate A, Dabul S, Lymperopoulos A

Drug Design, Development and Therapy 2013, 7:1209-1222

Published Date: 11 October 2013

New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol

Cazzola M, Segreti A, Matera MG

Drug Design, Development and Therapy 2013, 7:1201-1208

Published Date: 10 October 2013

8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications

Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V

Drug Design, Development and Therapy 2013, 7:1157-1178

Published Date: 4 October 2013

The effect of prostaglandin analogs on the biomechanical properties and central thickness of the cornea of patients with open-angle glaucoma: a 3-year study on 108 eyes

Tsikripis P, Papaconstantinou D, Koutsandrea C, Apostolopoulos M, Georgalas I

Drug Design, Development and Therapy 2013, 7:1149-1156

Published Date: 4 October 2013

Clinical experimentation with aerosol antibiotics: current and future methods of administration

Zarogoulidis P, Kioumis I, Porpodis K, Spyratos D, Tsakiridis K, Huang H, Li Q, Turner JF, Browning R, Hohenforst-Schmidt W, Zarogoulidis K

Drug Design, Development and Therapy 2013, 7:1115-1134

Published Date: 2 October 2013

Advances with microRNAs in Parkinson’s disease research

Ma L, Wei L, Wu F, Hu Z, Liu Z, Yuan W

Drug Design, Development and Therapy 2013, 7:1103-1113

Published Date: 1 October 2013

A novel dimeric thymosin beta 4 with enhanced activities accelerates the rate of wound healing

Xu TJ, Wang Q, Ma XW, Zhang Z, Zhang W, Xue XC, Zhang C, Hao Q, Li WN, Zhang YQ, Li M

Drug Design, Development and Therapy 2013, 7:1075-1088

Published Date: 1 October 2013

Amniotic fluid stem cells morph into a cardiovascular lineage: analysis of a chemically induced cardiac and vascular commitment

Maioli M, Contini G, Santaniello S, Bandiera P, Pigliaru G, Sanna R, Rinaldi S, Delitala AP, Montella A, Bagella L, Ventura C

Drug Design, Development and Therapy 2013, 7:1063-1073

Published Date: 27 September 2013

New structure–activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity

Rangel LP, Winter E, Gauthier C, Terreux R, Chiaradia-Delatorre LD, Mascarello A, Nunes RJ, Yunes RA, Creczynski-Pasa TB, Macalou S, Lorendeau D, Baubichon-Cortay H, Ferreira-Pereira A, Di Pietro A

Drug Design, Development and Therapy 2013, 7:1043-1052

Published Date: 30 September 2013

Preparation and characterization of 6-mercaptopurine-coated magnetite nanoparticles as a drug delivery system

Dorniani D, Hussein MZ, Kura AU, Fakurazi S, Shaari AH, Ahmad Z

Drug Design, Development and Therapy 2013, 7:1015-1026

Published Date: 25 September 2013

Vitamin D in asthma and future perspectives

Huang H, Porpodis K, Zarogoulidis P, Domvri K, Giouleka P, Papaiwannou A, Primikyri S, Mylonaki E, Spyratos D, Hohenforst-Schmidt W, Kioumis I, Zarogoulidis K

Drug Design, Development and Therapy 2013, 7:1003-1013

Published Date: 23 September 2013

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K

Drug Design, Development and Therapy 2013, 7:989-1001

Published Date: 17 September 2013

Unexpected effects of peripherally administered kynurenic acid on cortical spreading depression and related blood–brain barrier permeability

Oláh G, Herédi J, Menyhárt Á, Czinege Z, Nagy D, Fuzik J, Kocsis K, Knapp L, Krucsó E, Gellért L, Kis Z, Farkas T, Fülöp F, Párdutz Á, Tajti J, Vécsei L, Toldi J

Drug Design, Development and Therapy 2013, 7:981-987

Published Date: 16 September 2013

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis [Corrigendum]

Mazo DF, de Oliveira MG, Pereira IV, Cogliati B, Stefano JT, de Souza GF, Rabelo F, Lima FR, Ferreira Alves VA, Carrilho FJ, de Oliveira CP

Drug Design, Development and Therapy 2013, 7:971-972

Published Date: 13 September 2013

Long-acting preparations of exenatide

Cai Y, Wei L, Ma L, Huang X, Tao A, Liu Z, Yuan W

Drug Design, Development and Therapy 2013, 7:963-970

Published Date: 5 September 2013

Hologram quantitative structure–activity relationship and comparative molecular field analysis studies within a series of tricyclic phthalimide HIV-1 integrase inhibitors

Magalhães UO, Souza AMT, Albuquerque MG, Brito MA, Bello ML, Cabral LM, Rodrigues CR

Drug Design, Development and Therapy 2013, 7:953-961

Published Date: 5 September 2013

Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine

Hong X, Wei L, Wu F, Wu Z, Chen L, Liu Z, Yuan W

Drug Design, Development and Therapy 2013, 7:945-952

Published Date: 4 September 2013

Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study

Abdel-Razeq H, Abbasi S, Saadi I, Jaber R , Abdulelah H

Drug Design, Development and Therapy 2013, 7:939-944

Published Date: 30 August 2013

Identification of PPARγ ligands with One-dimensional Drug Profile Matching

Kovács D, Simon Z, Hári P, Málnási-Csizmadia A, Hegedűs C, Drimba L, Németh J, Sári R, Szilvássy Z, Peitl B

Drug Design, Development and Therapy 2013, 7:917-928

Published Date: 2 September 2013

Novel N-phenylcarbamothioylbenzamides with anti-inflammatory activity and prostaglandin E2 inhibitory properties

Limban C, Missir AV, Fahelelbom KMS, Al-Tabakha MM, Caproiu MT, Sadek B

Drug Design, Development and Therapy 2013, 7:883-892

Published Date: 28 August 2013

Bioequivalence study of two formulations of candesartan cilexetil tablet in healthy subjects under fasting conditions

Tjandrawinata RR, Setiawati E, Yunaidi DA, Simanjuntak R, Santoso ID, Susanto LW

Drug Design, Development and Therapy 2013, 7:841-847

Published Date: 20 August 2013

In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features

Xiang M, Lei K, Fan W, Lin Y, He G, Yang M, Chen L, Mo Y

Drug Design, Development and Therapy 2013, 7:789-839

Published Date: 14 August 2013

Clinical study of etomidate emulsion combined with remifentanil in general anesthesia

Weng D, Huang M, Jiang R, Zhan R, Yang C

Drug Design, Development and Therapy 2013, 7:771-776

Published Date: 20 August 2013

Valproic acid-associated low fibrinogen and delayed intracranial hemorrhage: case report and mini literature review

Chen HF, Xu LP, Luo ZY, Yu ZQ, Li ZY, Cui QY, Qin LM, Ren YY, Shen HS, Tang JQ, Jin LJ, Zhu JJ, Wang J, Wang KY, Wu TQ, Wang ZY

Drug Design, Development and Therapy 2013, 7:767-770

Published Date: 13 August 2013

N-Palmitoylethanolamine depot injection increased its tissue levels and those of other acylethanolamide lipids

Grillo SL, Keereetaweep J, Grillo MA, Chapman KD, Koulen P

Drug Design, Development and Therapy 2013, 7:747-752

Published Date: 12 August 2013

Developing therapeutic approaches for metachromatic leukodystrophy

Patil SA, Maegawa GHB

Drug Design, Development and Therapy 2013, 7:729-745

Published Date: 8 August 2013

Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis

Mahe J, Meurette A, Moreau A, Vercel C, Jolliet P

Drug Design, Development and Therapy 2013, 7:723-728

Published Date: 7 August 2013

Aflibercept in wet AMD: specific role and optimal use

Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C

Drug Design, Development and Therapy 2013, 7:711-722

Published Date: 5 August 2013

Mycobacterium marinum: a potential immunotherapy for Mycobacterium tuberculosis infection

Tian WW, Wang QQ, Liu WD, Shen JP, Wang HS

Drug Design, Development and Therapy 2013, 7:669-680

Published Date: 29 July 2013

Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial

Maneeton B, Maneeton N, Srisurapanont M, Chittawatanarat K

Drug Design, Development and Therapy 2013, 7:657-667

Published Date: 24 July 2013

Glyphosate and AMPA inhibit cancer cell growth through inhibiting intracellular glycine synthesis

Li Q, Lambrechts MJ, Zhang Q, Liu S, Ge D, Yin R, Xi M, You Z

Drug Design, Development and Therapy 2013, 7:635-643

Published Date: 24 July 2013

Successful application of extracorporeal membrane oxygenation due to pulmonary hemorrhage secondary to granulomatosis with polyangiitis

Hohenforst-Schmidt W, Petermann A, Visouli A, Zarogoulidis P, Darwiche K, Kougioumtzi I, Tsakiridis K, Machairiotis N, Ketteler M, Zarogoulidis K, Brachmann J

Drug Design, Development and Therapy 2013, 7:627-633

Published Date: 24 July 2013

Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a Phase II, randomized study

Zarogoulidis K, Ziogas E, Boutsikou E, Zarogoulidis P, Darwiche K, Kontakiotis T, Tsakiridis K, Porpodis K, Latsios D, Chatzizisi O, Karapantzos I, Li Q, Kyriazis G

Drug Design, Development and Therapy 2013, 7:611-617

Published Date: 23 July 2013

Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture

Rossini M, Lello S, Sblendorio I, Viapiana O, Fracassi E, Adami S, Gatti D

Drug Design, Development and Therapy 2013, 7:601-610

Published Date: 22 July 2013

Organelle targeting: third level of drug targeting

Sakhrani NM, Padh H

Drug Design, Development and Therapy 2013, 7:585-599

Published Date: 17 July 2013

Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies

Hohenforst-Schmidt W, Zarogoulidis P, Darwiche K, Vogl T, Goldberg EP, Huang H, Simoff M, Li Q, Browning R, Turner FJ, Le Pivert P, Spyratos D, Zarogoulidis K, Celikoglu SI, Celikoglu F, Brachmann J

Drug Design, Development and Therapy 2013, 7:571-583

Published Date: 18 July 2013

Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration

Panos GD, Gatzioufas Z, Petropoulos IK, Dardabounis D, Thumann G, Hafezi F

Drug Design, Development and Therapy 2013, 7:565-569

Published Date: 10 July 2013

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis

Mazo DF, de Oliveira MG, Pereira IV, Cogliati B, Stefano JT, de Souza GF, Rabelo F, Lima FR, Ferreira Alves VA, Carrilho FJ, de Oliveira CP

Drug Design, Development and Therapy 2013, 7:553-563

Published Date: 28 June 2013

Endogenous n 3 polyunsaturated fatty acids PUFAs mitigate ovariectomy-induced bone loss by attenuating bone marrow adipogenesis in FAT1 transgenic mice

Chen TY, Zhang ZM, Zheng XC, Wang L, Huang MJ, Qin S, Chen J, Lai PL, Yang CL, Liu J, Dai YF, Jin DD, Bai XC

Drug Design, Development and Therapy 2013, 7:545-552

Published Date: 28 June 2013

Drug-resistant colon cancer cells produce high carcinoembryonic antigen and might not be cancer-initiating cells

Lee HC, Ling QD, Yu WC, Hung CM, Kao TC, Huang YW, Higuchi A

Drug Design, Development and Therapy 2013, 7:491-502

Published Date: 17 June 2013

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration

Tranos P, Vakalis A, Asteriadis S, Koukoula S, Vachtsevanos A, Perganta G, Georgalas I

Drug Design, Development and Therapy 2013, 7:485-490

Published Date: 17 June 2013

Novel phytochemical–antibiotic conjugates as multitarget inhibitors of Pseudomononas aeruginosa GyrB/ParE and DHFR

Jayaraman P, Sakharkar KR, Lim CS, Siddiqi MI, Dhillon SK, Sakharkar MK

Drug Design, Development and Therapy 2013, 7:449-475

Published Date: 17 June 2013

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema

Messenger WB, Beardsley RM, Flaxel CJ

Drug Design, Development and Therapy 2013, 7:425-434

Published Date: 24 May 2013

Very rapid effect of pitavastatin on microvascular function in comparison to rosuvastatin: reactive hyperemia peripheral arterial tonometric study

Kono Y, Fukuda S, Shimada K, Nakanishi K, Otsuka K, Kubo T, Jissho S, Taguchi H, Yoshikawa J, Yoshiyama M

Drug Design, Development and Therapy 2013, 7:369-374

Published Date: 3 May 2013

Profile of certolizumab and its potential in the treatment of psoriatic arthritis

Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R

Drug Design, Development and Therapy 2013, 7:339-348

Published Date: 15 April 2013

Current and emerging pharmacological treatments for sarcoidosis: a review

Beegle SH, Barba K, Gobunsuy R, Judson MA

Drug Design, Development and Therapy 2013, 7:325-338

Published Date: 12 April 2013

In vitro and in vivo evaluation of a sublingual fentanyl wafer formulation

Lim SCB, Paech MJ, Sunderland B, Liu Y

Drug Design, Development and Therapy 2013, 7:317-324

Published Date: 12 April 2013

Usefulness of a selective neutrophil elastase inhibitor, sivelestat, in acute lung injury patients with sepsis

Miyoshi S, Hamada H, Ito R, Katayama H, Irifune K, Suwaki T, Nakanishi N, Kanematsu T, Dote K, Aibiki M, Okura T, Higaki J

Drug Design, Development and Therapy 2013, 7:305-316

Published Date: 10 April 2013

Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation

Gueler I, Mueller S, Helmschrott M, Oeing CU, Erbel C, Frankenstein L, Gleissner C, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA, Doesch AO

Drug Design, Development and Therapy 2013, 7:297-303

Published Date: 8 April 2013

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab

Armuzzi A, Pugliese D, Nardone OM, Guidi L

Drug Design, Development and Therapy 2013, 7:289-296

Published Date: 8 April 2013

Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics

Liu L, Ma Y, Wang RL, Xu WR, Wang SQ, Chou KC

Drug Design, Development and Therapy 2013, 7:279-288

Published Date: 8 April 2013

Phentermine and topiramate for the management of obesity: a review

Cosentino G, Conrad AO, Uwaifo GI

Drug Design, Development and Therapy 2013, 7:267-278

Published Date: 5 April 2013

Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections

Urbina O, Ferrández O, Espona M, Salas E, Ferrández I, Grau S

Drug Design, Development and Therapy 2013, 7:243-265

Published Date: 3 April 2013

Generalized in vitro-in vivo relationship (IVIVR) model based on artificial neural networks

Mendyk A, Tuszyński PK, Polak S, Jachowicz R

Drug Design, Development and Therapy 2013, 7:223-232

Published Date: 27 March 2013

Hepatocyte-targeting gene transfer mediated by galactosylated poly(ethylene glycol)- graft-polyethylenimine derivative

Wang YQ, Su J, Cai WW, Lu P, Yuan LF, Jin T, Chen SY, Sheng J

Drug Design, Development and Therapy 2013, 7:211-221

Published Date: 26 March 2013

A review of tasquinimod in the treatment of advanced prostate cancer

Williamson SC, Hartley AE, Heer R

Drug Design, Development and Therapy 2013, 7:167-174

Published Date: 21 March 2013

Successful management of an inadvertent excessive treprostinil overdose

Hohenforst-Schmidt W, Hornig J, Friedel N, Zarogoulidis P, Zarogoulidis K, Brachmann J

Drug Design, Development and Therapy 2013, 7:161-165

Published Date: 21 March 2013

Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells

Dai ZJ, Gao J, Kang HF, Ma YG, Ma XB, Lu WF, Lin S, Ma HB, Wang XJ, Wu WY

Drug Design, Development and Therapy 2013, 7:149-159

Published Date: 19 March 2013

The therapeutic efficacy of propranolol in children with recurrent primary epistaxis

Bjelakovic B, Bojanovic M, Lukic S, Saranac L, Vukomanovic V, Prijic S, Zivkovic N, Randjelovic D

Drug Design, Development and Therapy 2013, 7:127-129

Published Date: 1 March 2013

Advances with RNA interference in Alzheimer’s disease research

Chen S, Ge X, Chen Y, Lv N, Liu Z, Yuan W

Drug Design, Development and Therapy 2013, 7:117-125

Published Date: 22 February 2013

Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes

Giampietro O, Giampietro C, Della Bartola L, Masoni MC, Matteucci E

Drug Design, Development and Therapy 2013, 7:99-104

Published Date: 14 February 2013

Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation

Wu X, Hayes D Jr, Zwischenberger JB, Kuhn RJ, Mansour HM

Drug Design, Development and Therapy 2013, 7:59-72

Published Date: 4 February 2013

Risk factors in patients with AFB smear-positive sputum who receive inappropriate antituberculous treatment

Chang CY, Hong JY, Yuan MK, Chang SJ, Lee YM, Chang SC, Hsu LC, Cheng SL

Drug Design, Development and Therapy 2013, 7:53-58

Published Date: 31 January 2013

Emerging treatment options for nasopharyngeal carcinoma

Zhang L, Chen QY, Liu H, Tang LQ, Mai HQ

Drug Design, Development and Therapy 2013, 7:37-52

Published Date: 1 February 2013

Acetazolamide-induced cilio-choroidal effusion after cataract surgery: unusual posterior involvement

Malagola R, Arrico L, Giannotti R, Pattavina L

Drug Design, Development and Therapy 2013, 7:33-36

Published Date: 23 January 2013

Hippuric acid nanocomposite enhances doxorubicin and oxaliplatin-induced cytotoxicity in MDA-MB231, MCF-7 and Caco2 cell lines

Hussein Al Ali SH, Al-Qubaisi M, Hussein MZ, Ismail M, Bullo S

Drug Design, Development and Therapy 2013, 7:25-31

Published Date: 14 January 2013

Impact of ghrelin on vitreous cytokine levels in an experimental uveitis model

Turgut B, Gul FC, Dagli F, Ilhan N, Ozgen M

Drug Design, Development and Therapy 2013, 7:19-24

Published Date: 9 January 2013

New treatments for myasthenia: a focus on antisense oligonucleotides

Angelini C, Martignago S, Bisciglia M

Drug Design, Development and Therapy 2013, 7:13-17

Published Date: 10 January 2013

Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study

Ersoy H, Yaytokgil M, Karakoyunlu AN, Topaloglu H, Sagnak L, Ozok HU

Drug Design, Development and Therapy 2013, 7:1-6

Published Date: 28 December 2012